Clinical trial
Campath in Chronic GVHD
NCT00495755 · Dana-Farber Cancer Institute, Other · Completed
Key facts
| NCT number | NCT00495755 |
|---|---|
| Title | Campath in Chronic GVHD |
| Official title | An Open Label Phase I Trial of Alemtuzumab (Campath 1-H) Therapy for Refractory Chronic Graft-vs-Host Disease |
| Lead sponsor | Dana-Farber Cancer Institute, Other |
| Collaborators | Genzyme, a Sanofi Company Industry Bayer |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Chronic Graft-vs.-Host Disease |
| Intervention type | Drug |
| Interventions | Alemtuzumab (Campath) |
| Enrollment | 13 |
| Start date | Jul 1, 2007 |
| Primary completion | Oct 1, 2011 |
| Completion | Oct 1, 2012 |
| First posted | Jul 3, 2007 |
| Last update posted | Aug 9, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: